Investigative White Paper on Background, Cost Impact, and Legal Issues Relating to DIR Fees

A new White Paper by the law firm of Frier Levitt, LLC examines the ongoing practice by Pharmacy Benefit Managers (PBMs) to increase corporate profits through murky “direct and indirect remuneration” fees—commonly known as “DIR Fees”—charged to community oncology practices, as well as retail and specialty pharmacies (“Pharmacy Providers”).

DIR Fees, which have no basis in regulation or law, artificially inflate the costs paid by Medicare beneficiaries for prescription drugs, pushing them into the Medicare Part D “donut hole” faster, fueling rising drug prices, and ultimately adding to the burden on taxpayers.

Read the Full White Paper Here >>

By | 2018-10-12T15:06:15+00:00 June 26th, 2017|Resources|0 Comments